The Goldman Sachs Group Raises Definitive Healthcare (NASDAQ:DH) Price Target to $3.40

Definitive Healthcare (NASDAQ:DH) had its target price increased by research analysts at The Goldman Sachs Group from $3.00 to $3.40 in a report issued on Monday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. The Goldman Sachs Group’s target price indicates a potential downside of 5.56% from the company’s current price.

Other analysts also recently issued reports about the company. Barclays cut their price objective on Definitive Healthcare from $4.00 to $3.00 and set an “underweight” rating for the company in a research report on Monday, March 3rd. Needham & Company LLC reiterated a “hold” rating on shares of Definitive Healthcare in a research report on Thursday, January 16th. Finally, BTIG Research lowered shares of Definitive Healthcare from a “buy” rating to a “neutral” rating in a report on Friday, May 9th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, Definitive Healthcare currently has an average rating of “Hold” and a consensus target price of $5.10.

Definitive Healthcare Stock Up 0.6%

DH stock opened at $3.60 on Monday. Definitive Healthcare has a one year low of $2.15 and a one year high of $6.27. The firm has a market cap of $388.67 million, a PE ratio of -1.16, a PEG ratio of 4.06 and a beta of 1.48. The firm’s 50 day moving average price is $2.72 and its 200-day moving average price is $3.86. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.49 and a current ratio of 2.49.

Definitive Healthcare (NASDAQ:DH) last posted its earnings results on Thursday, May 8th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.03. Definitive Healthcare had a positive return on equity of 1.76% and a negative net margin of 142.38%. The company had revenue of $59.19 million during the quarter, compared to analysts’ expectations of $56.20 million. During the same quarter last year, the firm earned $0.08 earnings per share. The firm’s quarterly revenue was down 6.8% compared to the same quarter last year. On average, equities research analysts anticipate that Definitive Healthcare will post 0.16 EPS for the current year.

Hedge Funds Weigh In On Definitive Healthcare

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Tocqueville Asset Management L.P. boosted its stake in shares of Definitive Healthcare by 32.5% in the 1st quarter. Tocqueville Asset Management L.P. now owns 265,000 shares of the company’s stock valued at $766,000 after buying an additional 65,000 shares during the period. Nuveen LLC acquired a new stake in Definitive Healthcare in the first quarter valued at approximately $300,000. Invesco Ltd. raised its holdings in Definitive Healthcare by 19.3% in the first quarter. Invesco Ltd. now owns 61,871 shares of the company’s stock valued at $179,000 after acquiring an additional 10,012 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its stake in Definitive Healthcare by 70.6% in the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 250,152 shares of the company’s stock worth $723,000 after acquiring an additional 103,529 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in Definitive Healthcare by 9.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 458,936 shares of the company’s stock worth $1,326,000 after acquiring an additional 38,443 shares in the last quarter. Hedge funds and other institutional investors own 98.67% of the company’s stock.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.